What is D&D Pharmatech?
D&D Pharmatech operates as a specialized clinical-stage global biotech enterprise that leverages a decentralized subsidiary structure to accelerate medical innovation. By founding and guiding disease-specific entities led by top-tier medical research faculty, the company effectively bridges the gap between academic discovery and commercial pharmaceutical development. With a dual-presence in Korea and the United States, D&D Pharmatech maintains a strategic advantage in accessing global talent and capital markets, positioning itself as a key player in the advancement of next-generation medicine.
How much funding has D&D Pharmatech raised?
D&D Pharmatech has raised a total of $198.9M across 3 funding rounds:
Series B
$137.1M
Series C
$51M
Debt
$10.8M
Series B (2019): $137.1M with participation from Smilegate Investment, Octave Life Sciences, LB Investment, Magna Investment, and InterVest
Series C (2021): $51M led by DS Asset Management, KOREA INVESTMENT & SECURITIES, Kudos Venture Capital, and Praxis Capital Partners
Debt (2025): $10.8M, investors not publicly disclosed
Key Investors in D&D Pharmatech
DS Asset Management
An investment management firm that focuses on deep insights into companies and industries to foster trusted partnerships with clients for mutual growth.
KOREA INVESTMENT & SECURITIES
A major financial firm within Korea Investment Holdings that specializes in asset management, securities brokerage, and investment banking.
Kudos Venture Capital
A boutique venture capital firm focused on early-stage, innovative companies within the healthcare and life science sectors.
What's next for D&D Pharmatech?
With the recent influx of capital, D&D Pharmatech is well-positioned to advance its clinical trials and expand its portfolio of subsidiary-led research initiatives. The company's strategic roadmap likely involves scaling its operational footprint to support late-stage development, while simultaneously exploring potential licensing agreements or strategic partnerships to bring its therapeutic assets to market. As the firm continues to refine its business model, the focus will remain on achieving sustainable growth through the successful commercialization of its diverse medical pipeline, further cementing its reputation as a leader in the biotech investment landscape.
See full D&D Pharmatech company page
